Choate Investment Advisors Has $38.34 Million Stock Holdings in Abbott Laboratories $ABT

Key Points

• Choate Investment Advisors increased its Abbott Laboratories stake by 9.3% in the fourth quarter, adding 26,019 shares to reach 305,976 shares valued at about $38.34 million.
• Abbott reported better-than-expected first-quarter results, with EPS of $1.15 on revenue of $11.16 billion, and it raised guidance for FY2026 to $5.38–$5.58 EPS.
• Analyst sentiment remains constructive but slightly cautious: several firms cut price targets, while the stock still carries a Moderate Buy consensus with an average target of $119.43.

Choate Investment Advisors raised its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 9.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 305,976 shares of the healthcare product maker's stock after acquiring an additional 26,019 shares during the quarter. Abbott Laboratories comprises approximately 0.8% of Choate Investment Advisors' holdings, making the stock its 23rd largest position. Choate Investment Advisors' holdings in Abbott Laboratories were worth $38,336,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Sandy Cove Advisors LLC lifted its stake in shares of Abbott Laboratories by 13.5% in the fourth quarter. Sandy Cove Advisors LLC now owns 1,753 shares of the healthcare product maker's stock worth $220,000 after buying an additional 208 shares during the last quarter. Sectoral Asset Management Inc. lifted its stake in shares of Abbott Laboratories by 36.6% in the fourth quarter. Sectoral Asset Management Inc. now owns 23,498 shares of the healthcare product maker's stock worth $2,944,000 after buying an additional 6,300 shares during the last quarter. CYBER HORNET ETFs LLC lifted its stake in shares of Abbott Laboratories by 5.5% in the fourth quarter. CYBER HORNET ETFs LLC now owns 5,120 shares of the healthcare product maker's stock worth $641,000 after buying an additional 265 shares during the last quarter. Churchill Financial Advisors LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $1,144,000. Finally, Main Street Research LLC lifted its stake in shares of Abbott Laboratories by 3.5% in the fourth quarter. Main Street Research LLC now owns 3,654 shares of the healthcare product maker's stock worth $458,000 after buying an additional 123 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the company's stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company's stock, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,055 shares of company stock worth $353,097. Insiders own 0.46% of the company's stock.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. Oppenheimer reduced their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. Piper Sandler reduced their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating for the company in a research note on Friday, April 17th. The Goldman Sachs Group reduced their price objective on shares of Abbott Laboratories from $140.00 to $121.00 and set a "buy" rating for the company in a research note on Wednesday, April 8th. Freedom Capital upgraded shares of Abbott Laboratories from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 29th. Finally, Mizuho cut their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating for the company in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $119.43.

Abbott Laboratories Price Performance

NYSE:ABT opened at $87.42 on Monday. The stock has a market cap of $152.27 billion, a P/E ratio of 24.49, a PEG ratio of 1.46 and a beta of 0.65. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company has a fifty day moving average price of $96.74 and a 200 day moving average price of $111.97. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analysts' expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business's quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: A TipRanks roundup highlighted Abbott as one of three “Strong Buy” dividend aristocrat stocks with more than 15% upside potential, which may support investor confidence in the name. 3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26
• Positive Sentiment: Another piece argued that Abbott’s Lingo wearable and increased cardiovascular R&D could strengthen its long-term growth outlook by expanding its health-tech and diagnostics footprint. Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story
• Neutral Sentiment: One market note said traders are waiting for more clarity on integration results, suggesting investors are in a “show-me” phase rather than fully repricing the stock higher. Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)
• Negative Sentiment: Another article said Abbott has been “slid” in part because its nutrition segment is sensitive to consumer spending trends, highlighting macro pressure on a key business line. Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum
• Negative Sentiment: Goldman Sachs reportedly removed Abbott from its U.S. Conviction List, which may weigh on sentiment even though it does not change the company’s fundamentals. Why UnitedHealth (UNH) Remains a Turnaround Bet Despite Policy and Cost Pressure

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.